[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

ATE284711T1 - Heilmittel und/oder prophylactische mittel zur behandlung von nervensystem-störungen - Google Patents

Heilmittel und/oder prophylactische mittel zur behandlung von nervensystem-störungen

Info

Publication number
ATE284711T1
ATE284711T1 AT00987648T AT00987648T ATE284711T1 AT E284711 T1 ATE284711 T1 AT E284711T1 AT 00987648 T AT00987648 T AT 00987648T AT 00987648 T AT00987648 T AT 00987648T AT E284711 T1 ATE284711 T1 AT E284711T1
Authority
AT
Austria
Prior art keywords
calcium
nervous system
system disorders
medicinal
treatment
Prior art date
Application number
AT00987648T
Other languages
English (en)
Inventor
Satoshi Yuki
Naruhiko Yoshii
Original Assignee
Mitsubishi Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mitsubishi Pharma Corp filed Critical Mitsubishi Pharma Corp
Application granted granted Critical
Publication of ATE284711T1 publication Critical patent/ATE284711T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/096Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychology (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT00987648T 1999-12-21 2000-12-20 Heilmittel und/oder prophylactische mittel zur behandlung von nervensystem-störungen ATE284711T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP36268099 1999-12-21
JP2000065272 2000-03-09
PCT/JP2000/009024 WO2001045739A1 (fr) 1999-12-21 2000-12-20 Remedes et/ou medicaments preventifs pour troubles du systeme nerveux

Publications (1)

Publication Number Publication Date
ATE284711T1 true ATE284711T1 (de) 2005-01-15

Family

ID=26581413

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00987648T ATE284711T1 (de) 1999-12-21 2000-12-20 Heilmittel und/oder prophylactische mittel zur behandlung von nervensystem-störungen

Country Status (10)

Country Link
US (1) US7652017B2 (de)
EP (1) EP1249245B1 (de)
KR (1) KR100740477B1 (de)
CN (1) CN100486574C (de)
AT (1) ATE284711T1 (de)
AU (1) AU2398001A (de)
CA (1) CA2394633A1 (de)
DE (1) DE60016803T2 (de)
ES (1) ES2233493T3 (de)
WO (1) WO2001045739A1 (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2440670A1 (en) * 2001-03-13 2002-09-19 Mitsubishi Pharma Corporation Agent for therapeutic and/or prophylactic treatment of diabetic ischemic heart disease
CA2454681A1 (en) * 2001-07-25 2003-02-06 Mitsubishi Pharma Corporation Medicament inhibiting sodium/calcium exchange system
EP1419775A1 (de) * 2001-07-30 2004-05-19 Mitsubishi Pharma Corporation Pharmazeutische zubereitungen mit aminobenzol-sulfonsäurederivaten als wirkstoff
JPWO2004022545A1 (ja) * 2002-09-06 2005-12-22 三菱ウェルファーマ株式会社 移植臓器保護剤
WO2004069275A1 (ja) * 2003-02-04 2004-08-19 Mitsubishi Pharma Corporation 眼科用剤
US20070129441A1 (en) * 2003-05-06 2007-06-07 University Of North Texas Health Science Center At Fort Worth Protection of cells from adverse external or intrinsic effects, cellular degeneration and death by n-acylethanolamines
US20060142395A1 (en) * 2003-05-06 2006-06-29 University Of North Texas Health Science Center Modulation of intracellular calcium signaling by N-acylethanolamines
AU2021239199A1 (en) * 2020-03-19 2022-10-06 Sea6 Energy Pvt. Ltd. Composite, process for preparing the composite, and implementation thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0233728A1 (de) * 1986-02-11 1987-08-26 Takeda Chemical Industries, Ltd. 1,4-Benzoxazin-Derivate, ihre Herstellung und Verwendung
JPH0686438B2 (ja) 1989-03-27 1994-11-02 三菱化成株式会社 アミノベンゼンスルホン酸誘導体
US5053409A (en) * 1989-03-27 1991-10-01 Mitsubishi Kasei Corporation Aminobenzenesulfonic acid derivatives
GB9226111D0 (en) 1992-12-15 1993-02-10 Smithkline Beecham Plc Madicaments
JPH08504792A (ja) 1992-12-22 1996-05-21 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー カルシウムチャンネルアンタゴニストとしてのピペリジン誘導体
CA2192731C (en) * 1995-12-15 2005-09-27 Chika Yamazaki Monohydrates of aminobenzenesulfonic acid derivatives and method for preparing thereof

Also Published As

Publication number Publication date
US7652017B2 (en) 2010-01-26
EP1249245A4 (de) 2003-06-11
KR100740477B1 (ko) 2007-07-19
ES2233493T3 (es) 2005-06-16
WO2001045739A1 (fr) 2001-06-28
DE60016803D1 (de) 2005-01-20
EP1249245B1 (de) 2004-12-15
DE60016803T2 (de) 2005-12-29
CN100486574C (zh) 2009-05-13
CN1434724A (zh) 2003-08-06
AU2398001A (en) 2001-07-03
KR20020063254A (ko) 2002-08-01
US20030114427A1 (en) 2003-06-19
CA2394633A1 (en) 2001-06-28
EP1249245A1 (de) 2002-10-16

Similar Documents

Publication Publication Date Title
GB0005251D0 (en) Therapeutic compounds
ATE305306T1 (de) Reboxetin zur behandlung von peripheren neuropathien
ATE218854T1 (de) Behandlung von herzrythmusstörungen durch hemmung einer multifunktionalen calcium/calmodulin- abhängigen protein kinase
DE60114580D1 (de) Verwendung von cyanochinolinen zur behandlung oder inhibierung von dickdarmpolypen
GB0225474D0 (en) Therapeutic agents
DE60021266D1 (de) Verwendungen von zusammensetzungen zur behandlung oder vermeidung von schlafstörungen mit sehr niedrigdosierten cyclobenzaprine
ATE350030T1 (de) Nordihydroguaiaretinsäurederivate zur behandlung von tumoren
HK1042247A1 (en) Use of benzazepine-n ethanoic acid derivatives forpreparation of medicament for treating pulmonary hypertension.
BG106118A (en) Method for the treatment of fibrosis using an antagonist of the integrin alpha-4 subunit
DE69935853D1 (de) Anwendung von alfa1beta1 integrinrezeptorinhibitoren und tgf-beta1-inhibitoren zur behandlung von nierenkrankheiten
ATE284711T1 (de) Heilmittel und/oder prophylactische mittel zur behandlung von nervensystem-störungen
ATE214272T1 (de) Topische verwendung von kappa- opioidrezeptoragonisten zur behandlung von augenschmerz
ATE332705T1 (de) Verwendung von in der mittlere oder späte follikuläre phase verabreichte lh zur behandlung von anovulatorischen frauen
ATE234617T1 (de) Verwendung des saredutant und seiner pharmazeutisch akzeptablen salze zur behandlung von schwere depression
DE60036122D1 (de) Verwendung von eplerenon zur behandlung von restenose
DE69925578D1 (de) Pharmazeutische zusammenstellung zur vorbeugung und behandlung von mit zellkrankheiten des augenhintergrundes zusammenhängenden krankheiten
BR0007686A (pt) Uso de antagonistas receptores da angiotensina ii para tratar enfartação miocárdia aguda
DK1152757T3 (da) MMP-inhibitorer i bindevævsblödhed
ATE294584T1 (de) Verwendung von desoxypeganin zur behandlung von alzheimerischer demenz
GB9929497D0 (en) Improved amino acid mixtures for the treatment and/or management of certain diseases
ATE262362T1 (de) Verwendung von cyamemazin zur behandlung von entwöhnungserscheinungen der benzodiazepinbehandlung
WO2002024727A3 (en) New inhibitors of iapp fibril formation and uses thereof
DE69906701D1 (de) Topische verwendung von loperamid zur behandlung mikrobieller infektionen
ATE278401T1 (de) Verwendung von riluzol zur behandlung von akustischen traumazuständen
ID20165A (id) Penggunaan asam 2-(3,4-dimetoksisinamoil)aminobenzoat untuk pembuatan obat untuk pengobatan atau pencegahan restenosis

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties